Markets Navigate Hormuz Shock, Chip Jitters, and FedEx Paradox
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Macro: Hormuz Blockade Rattles Trade
The biggest macro story today is the Strait of Hormuz. Nearly 1,200 cargo ships carrying $125 billion in goods are stranded. Insurer Allianz called it an "unprecedented" blockade. Energy markets are feeling it. XOM options showed unusual depth across expiries through late September — traders are hedging for prolonged disruption, not a quick fix.
Chips: South Korea Sparks Contagion
South Korean chip stocks triggered a global ripple. Volatility in Samsung and SK Hynix hit record highs on AI demand doubts. That anxiety hit US names too. NVDA saw same-day options contracts trade heavily today — a sign of intraday hedging rather than long-term positioning. NVDA carries a $5 trillion market cap and just 1.2% short interest, so options remain the primary tool for risk management here.
Earnings: FedEx Beats, Drops Anyway
FDX beat on Q4 earnings and completed its freight spin-off. The stock fell anyway. That kind of sell-the-news reaction signals cautious sentiment. PAYX delivered a better story. The payroll giant beat and guided FY2027 adjusted EPS to $5.90–$6.01 against a $5.90 estimate. Tonight, all eyes turn to MU. The memory chipmaker reports Q3 2026 results after the close. AI-driven demand in its data centre segment is the key watch.
Pharma: Lilly Eyes China GLP-1 Win
LLY grabbed attention on reports that China could approve its GLP-1 pill as soon as 2026. That is a major addressable market. Separately, Novartis signed a deal with Antares Therapeutics, paying $105 million upfront to target difficult-to-treat cancer pathways.
Europe: Euro Slips, Defence Rallies
The euro fell to a one-year low as sliding oil prices reduced inflation pressure on the ECB. Defence stocks bucked the broader European slide after Ukraine ratified a $105 billion EU loan deal. Tankmaker KNDS also kicked off its Frankfurt and Paris dual-listing process, testing investor appetite for defence IPOs.
Stocks in this article
How this article was generated
- Generated
- 24 Jun 2026, 12:53
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.